Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Operating Leases (2019 - 2025)

Theravance Biopharma (TBPH) has disclosed Operating Leases for 7 consecutive years, with $31.8 million as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 18.79% to $31.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $31.8 million through Dec 2025, down 18.79% year-over-year, with the annual reading at $31.8 million for FY2025, 18.79% down from the prior year.
  • Operating Leases for Q4 2025 was $31.8 million at Theravance Biopharma, down from $33.7 million in the prior quarter.
  • The five-year high for Operating Leases was $57.8 million in Q2 2021, with the low at $31.8 million in Q4 2025.
  • Average Operating Leases over 5 years is $44.7 million, with a median of $43.8 million recorded in 2023.
  • The sharpest move saw Operating Leases grew 21.28% in 2021, then dropped 19.97% in 2023.
  • Over 5 years, Operating Leases stood at $52.7 million in 2021, then dropped by 13.81% to $45.4 million in 2022, then dropped by 0.38% to $45.2 million in 2023, then fell by 13.55% to $39.1 million in 2024, then decreased by 18.79% to $31.8 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $31.8 million, $33.7 million, and $35.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.